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LEADING ARTICLE
The Montreal classification of inflammatory bowel disease:
controversies, consensus, and implications
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In recent years, investigators have readdressed the
complex issues involved in the classification of
inflammatory bowel diseases. In 2003, a Working Party of
investigators with an interest in the issues involved in
disease subclassification was formed with the aim of
summarising recent developments in disease classification
and establishing an integrated clinical, molecular, and
serological classification of inflammatory bowel disease.
The results of the Working Party were reported at the 2005
Montreal World Congress of Gastroenterology. Here we
highlight the key issues that have emerged from discussions
of the Montreal Working Party and the relevance to clinical
practice and research activities.
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I
n recent years, several stimuli have led
investigators to readdress the complex issues
involved in the classification of inflammatory
bowel diseases. From the clinician’s perspective,
accurate classification of these diseases would
have potential benefits with respect to patient
counselling, assessing disease prognosis, and
particularly with choosing the most appropriate
therapy for each disease subtype. The perspec-
tives of basic scientists have been subtly differ-
ent, driven by an attempt to understand the
pathophysiology of the different manifestations
of Crohn’s disease, ulcerative colitis, and inde-
terminate colitis. Overlap between the clinical
and research based agendas has become even
more apparent with identification of novel
genetic determinants and serological markers
which have proven useful with respect to
subclassifying disease at the bedside, but may
also allow new insights into disease pathogen-
esis.
In 2003, a Working Party of investigators with
an interest in the issues involved in disease
subclassification was formed, with the objective
of summarising recent developments in disease
classification and examining the practicability of
developing an integrated clinical, molecular, and
serological classification of inflammatory bowel
disease. The results of the Working Party were
reported at the 2005 Montreal World Congress of
Gastroenterology.1 A number of key issues were
addressed at length, and controversies, consen-
sus issues, as well as a research agenda were
identified. The present review highlights the key
issues that have emerged from discussions of the
Montreal Working Party and the relevance to
clinical practice and research activities.
CLINICAL CLASSIFICATION OF CROHN’S
DISEASE: FROM VIENNA TO MONTREAL
The issues of subclassification of Crohn’s disease
by phenotype have been reviewed in recent years.
The International Working Party that issued its
report in Rome in 1991 proposed a classification
based on anatomical distribution, operative
history, and clinical behaviour (inflammatory,
fistulising, or stenotic disease). However, this
classification was felt inappropriate for clinical
application in the following years, and the World
Congress of Gastroenterology in Vienna in 1998
provided an opportunity for reconsidering and
reanalysis of this classification.2 The resulting
Vienna classification of Crohn’s disease consid-
ered age of onset (A), disease location (L), and
disease behaviour (B) as the predominant
phenotypic elements. Although the Vienna clas-
sification is still not widely used in clinical
practice, researchers have increasingly returned
to it and have assessed its applicability and
utility. The Montreal revision of the Vienna
classification has not changed the three predom-
inant parameters of age at diagnosis, location,
and behaviour, but modifications within each of
these categories have been made.
With respect to age of onset, the Montreal
classification allows for early onset of disease to be
categorised separately as a new A1 category for
those with age of diagnosis at 16 years or younger,
whereas A2 and A3 account for age of diagnosis at
17–40 years and .40 years, respectively (table 1).
This change reflects numerous studies demonstrat-
ing that specific serotypes or genotypes are more
frequently found in early onset Crohn’s disease.3–6
These findings may reflect the presence of specific
biomarkers in this subset of patients but equally
likely may illustrate the importance of this cohort
in identification of novel genetic and serological
markers. The modification was largely to allow for
the investigation and categorisation of paediatric
onset disease, both in clinical practice and for
molecular and serological studies.
‘‘With respect to disease location, the major
limitation of the Vienna classification was felt
to be that each of the four locations described
were mutually exclusive’’
With respect to disease location, the major
limitation of the Vienna classification was felt to
be that each of the four locations described were
Abbreviations: IBDU, inflammatory bowel disease, type
unclassified; ASCA, anti-Saccharomyces cerevisiae
antibody; ANCA, antineutrophil cytoplasmic
autoantibody
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mutually exclusive. The major difficulty had arisen with the
inability of the Vienna classification to allow upper gastro-
intestinal disease to coexist with more distal disease. As
investigations for upper gastrointestinal involvement become
more accessible and feasible with the introduction of wireless
capsule endoscopy, it is apparent that upper gastrointestinal
disease is relatively common, and may coexist with ileal and
with colonic disease. Therefore, in the revised Montreal
classification these parameters are no longer mutually
exclusive.
Finally, two critical issues were identified for integration into
the Montreal classification regarding disease behaviour. There
are now substantial data that perianal fistulising disease is not
necessarily associated with intestinal fistulising disease, and it
was felt that perianal disease alone required separate sub-
classification.7 A further issue with regard to classification of
disease behaviour is the observation that disease behaviour is
dynamic over time. Recent studies have reinforced this,
demonstrating that patients with predominantly inflammatory
disease at diagnosis are very likely to develop either fistulising or
stricturing complications within 5, 10, and 20 years.7 The
authors of the Montreal classification considered at length
whether a stipulated time point should be given before disease
behaviour might be classified. This approach was seen to have
both benefit as well as limitations, particularly in comparing
studies from different centres, and also in retrospective
analyses. The consensus statement allows for a stipulated time
to be set in studies of this aspect of disease. It should also be
noted that these changes to disease location and behaviour are
supported by an evolving body of evidence demonstrating that
site of disease, behaviour, and disease progression are all
variables that are likely to be identified by genetic and
serological markers.8–11
ULCERATIVE COLITIS
In contrast with Crohn’s disease, neither the Rome nor the
Vienna Working Parties had addressed subclassification of
ulcerative colitis. On reviewing the present literature, a
subclassification system for ulcerative colitis incorporating
an assessment of disease extent and severity of an individual
relapse of disease were felt to be of critical relevance for
recommendation by the Working Party. However, unmet
needs were clearly apparent in discussion, of which the most
acute appeared to be the need for a classification of
longitudinal disease progression, or disease behaviour over
time—that is, the frequency of disease relapse and course of
disease during the natural history.
The Montreal classification of disease extent of ulcerative
colitis allows extent to be defined into three subgroups (table 2).
The subclassification was felt to have clear biological
relevance in terms of the response of patients to medical
therapy (differential response to topical therapy), and also to
be validated by the natural history of the disease, with respect
to rates of medication usage, hospitalisation, or colectomy.
Moreover, the risk of colorectal malignancy was also felt to
provide further validation for this subclassification. In
addition, numerous studies show association of specific
serological and genetic markers with extensive ulcerative
colitis, making this subset of particular importance in the
study of its pathophysiology.12 13
‘‘The major drawback of the extent based classification
system was clearly identified to be instability of disease
extent over time, once again underlining the dynamic
nature of inflammatory bowel disease’’
The major drawback of the extent based classification
system was clearly identified to be instability of disease
extent over time, once again underlining the dynamic nature
of inflammatory bowel disease. Progression of disease extent
over time, together with regression, have been well identified
and accepted. The actual risk of proximal extension of
proctitis over 10 years is estimated to be as great as 41–54%.1
Progression of left sided colitis may be even higher. The
contrary observation is also valid—that disease extent may
regress over time, with regression rates estimated from a
crude rate of 1.6% to an actual rate of 71% after 10 years.1 In
light of this, the Montreal classification proposes the
maximal extent of involvement as the critical parameter.
Table 1 Vienna and Montreal classification for Crohn’s disease
Vienna Montreal
Age at diagnosis A1 below 40 y A1 below 16 y
A2 above 40 y A2 between 17 and 40 y
A3 above 40 y
Location L1 ileal L1 ileal
L2 colonic L2 colonic
L3 ileocolonic L3 ileocolonic
L4 upper L4 isolated upper disease*
Behaviour B1 non-stricturing, non-penetrating B1 non-stricturing, non-penetrating
B2 stricturing B2 stricturing
B3 penetrating B3 penetrating
p perianal disease modifier
*L4 is a modifier that can be added to L1–L3 when concomitant upper gastrointestinal disease is present.
‘‘p’’ is added to B1–B3 when concomitant perianal disease is present.
Table 2 Montreal classification of extent of ulcerative colitis (UC)
Extent Anatomy
E1 Ulcerative proctitis Involvement limited to the rectum (that is, proximal extent of
inflammation is distal to the rectosigmoid junction)
E2 Left sided UC (distal UC) Involvement limited to a proportion of the colorectum distal to the
splenic flexure
E3 Extensive UC (pancolitis) Involvement extends proximal to the splenic flexure
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The Working Party has suggested the classification of severity
of relapse into four disease activity/severity categories (table 3).
The term fulminant colitis is in variable use, and the
Working Party felt that the research agenda in ulcerative
colitis must address whether this term has prognostic, value
or clinical utility, contrasted with severe relapse of ulcerative
colitis, or should be abandoned. Further issues for the
research agenda in classification of ulcerative colitis have
been identified, and these will need to be addressed. The
issue of classification of disease behaviour over time has
considerable importance with respect to clinical manage-
ment, and may also have a direct implication with respect to
genetic studies. One of the few studies to have addressed this
to date are the detailed studies from Copenhagen where
patients with ulcerative colitis were classified into those with
prolonged remission, those with intermittent symptoms, and
those with continuous disease activity.14 Validation of this
classification system and introduction into a further classi-
fication scheme may well be directly helpful but will require
examination of cohorts of patients, identified either retro-
spectively or prospectively.
‘‘At the present time, evidence to introduce age of onset as
a separate subgroup in ulcerative colitis was felt to be
unproven’’
At the present time, evidence to introduce age of onset as a
separate subgroup in ulcerative colitis was felt to be
unproven, either with respect to clinical utility or in a basic
research agenda. Other issues that clearly require considera-
tion in a research agenda would be the need for separate
classification of colonic disease associated with sclerosing
cholangitis. Disease behaviour, extent, and malignancy risk
in cohorts of patients with concomitant primary sclerosing
cholangitis is increasingly well characterised and, although
uncommon, the need for these patients to have a separate
classification may well become apparent in further studies.
INDETERMINATE COLITIS
There is considerable confusion about the appropriate use of the
term indeterminate colitis. The Working Party reviewed the
initial definition introduced by Ashley Price in 1978.15 Price
suggested that the diagnosis be made only following colectomy
in patients in whom the features were not sufficient to allow a
diagnosis of either Crohn’s disease or ulcerative colitis but were
sufficient to allow a diagnosis of inflammatory bowel disease
affecting the colon. In subsequent years, the use of the term has
been widened by clinicians to allow for patients in whom
inflammatory bowel disease affecting the colon is apparent on
clinical and endoscopic features but in whom histology and all
other clinical parameters do not allow a clear diagnosis of either
Crohn’s disease or ulcerative colitis.
The Montreal Working Party has recommended that the
term ‘‘indeterminate colitis’’ should be reserved only for those
cases where colectomy has been performed and pathologists
are unable to make a definitive diagnosis of either Crohn’s
disease or ulcerative colitis after full examination. In contrast,
the term ‘‘inflammatory bowel disease, type unclassified’’
(IBDU) is suggested for patients in whom there is evidence on
clinical and endoscopic grounds for chronic inflammatory
bowel disease affecting the colon, without small bowel
involvement, and no definitive histological or other evidence
to favour either Crohn’s disease or ulcerative colitis. In these
patients, clearly infection would have been ruled out before
the term IBDU might be applied.
‘‘The Montreal Working Party has recommended that the
term ‘‘indeterminate colitis’’ should be reserved only for
those cases where colectomy has been performed and
pathologists are unable to make a definitive diagnosis of
either Crohn’s disease or ulcerative colitis after full
examination’’
The Working Party discussed the prospects for the use of
serological and genetic markers in refining the classification
of indeterminate colitis and IBDU further. Both established
serological markers (anti-Saccharomyces cerevisiae antibody
(ASCA), antineutrophil cytoplasmic autoantibody (ANCA))
and novel markers currently emerging (OmpC, cBir flagellin,
I2) were felt to carry the potential for helping further the
understanding of the classification of these entities.13 The
research agenda in this area focused heavily on the need for
further integration of serological and genetic markers in
these patients, and the need for prospective analyses as to
whether a combination of currently available markers might
help in predicting the further course of patients with colonic
IBDU. In addition, it was felt strongly that the increasing use
of capsule endoscopy, and novel diagnostic methods in the
relatively near future, lead to a further need to revisit this
classification scheme.
INTEGRATED MOLECULAR DIAGNOSIS OF IBD
Although the initial catalyst for the inception of the Working
Party had been the goal of developing an integrated
classification scheme, involving clinical, serological, and
genetic markers, there was widespread agreement within
the Working Party that such an integrated classification is
not at present justified. However, the progress and interest in
this area is evident, and subgroups of the Working Party
examined in detail the current stage of knowledge with
respect to serological markers, specific genetic markers, and
the importance of geographical and ethnic variation: all of
these reports were felt essential in defining a further research
agenda for an integrated classification.
Serological markers
The two most widely studied serological markers in
inflammatory bowel disease in recent years have been
p-ANCA and ASCA. The clinical utility of p-ANCA or ASCA
testing in the diagnosis of inflammatory bowel disease, in
patients with non-specific gastrointestinal symptoms, is
limited because of the varying seroprevalence of these
antibodies in patients with inflammatory bowel disease and
the inadequate sensitivity of the assays. The Working Party
Table 3 Montreal classification of severity of ulcerative colitis (UC)
Severity Definition
S0 Clinical remission Asymptomatic
S1 Mild UC Passage of four or fewer stools/day (with or without blood), absence of any
systemic illness, and normal inflammatory markers (ESR)
S2 Moderate UC Passage of more than four stools per day but with minimal signs of systemic toxicity
S3 Severe UC Passage of at least six bloody stools daily, pulse rate of at least 90 beats per minute,
temperature of at least 37.5 C˚, haemoglobin of less than 10.5 g/100 ml, and ESR of
at least 30 mm/h
ESR, erythrocyte sedimentation rate.
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felt unable to recommend the use of these serological
markers in routine clinical practice as diagnostic tools at
present; the potential advantages of non-invasive testing,
even in triaging patients for definitive investigation, particu-
larly in children, were noted and discussed.
The prospects for widening the panel of serological
markers, to increase diagnostic specificity and sensitivity
and also to help subclassify inflammatory bowel disease, was
reviewed in some detail, in view of the number of recent
papers suggesting that serological responses to microbial
antigens may help advance this area. Most progress has been
made with respect to substratification of Crohn’s disease,
with the identification of novel markers (anti-OMPC and
anti-I2, and most recently the anti-CBir1 flagellin antibo-
dies).16 Consistent data now suggest that the combination of
ASCA, ANCA, anti-OmpC, and anti-I2 may help in the
subclassification of Crohn’s disease, in particular that these
serological markers are associated with a complicated and
severe disease behaviour, including need for surgery.10 11
‘‘In concluding the assessment of the role of serological
markers at the present time, the Working Party determined
that the use of these markers for diagnosis is not currently
justified, given the limited sensitivity of available markers’’
The research agenda for this field included the need for
independent validation and the need for a minimal dataset
for research studies. In concluding the assessment of the role
of serological markers at the present time, the Working Party
determined that the use of these markers for diagnosis is not
currently justified, given the limited sensitivity of available
markers. Similarly, therapeutic decisions in patients with
indeterminate colitis may not at the present time rely on
serological markers alone. However, the prospects for
development in this area were emphasised by the Working
Party—identification of novel markers and novel serotype-
phenotype relationships—and may not only help understand
disease pathophysiology but also be of clinical use. The need
for independently executed studies with consistent pheno-
typic description of the patients involved was felt to be a
critical item for progress.
Role of genetic markers in disease classification:
progress and prospects
Although identification of the NOD2/CARD15 gene was again a
strong catalyst for the research carried out by the Working
Party, members of the Working Party were unanimous in
feeling that integration of NOD2/CARD15 genotype, or other
genetic markers, could not be justified on current evidence. The
current literature supports the finding that CARD15 variants are
consistently more common in Caucasian patients with Crohn’s
disease than in healthy controls, and that a gene dosage effect
exists. The overall risk for developing Crohn’s disease in simple
heterozygotes (in whom there is one variant and one wild-type
chromosome) is suggested by recent analysis and by meta-
analysis to be in the region of 2.4 (95% confidence intervals 2.0–
2.9) and the risk for persons with two mutant chromosomes
(simple homozygotes or compound heterozygotes) was esti-
mated at meta-analysis to be 17.1 (confidence intervals 10.7–
27.2).17 In Asians, Arabs, Africans, and African Americans the
contribution of these variants and genotype risks are either
reduced or entirely absent.18 However, even within Europe there
is clearly variation in the importance of the NOD2/CARD15
allelic variants in contributing towards disease susceptibility—
the importance of these variants in Northern Europe
(Scandinavia, Scotland, Ireland) is less than in the index
studies reported from Central Europe, and the intriguing
possibility that different founder effects are important in
Northern European populations with Crohn’s disease has
emerged.19 20 The complexities of heterogeneity between
populations is further compounded by the heterogeneity within
populations and genotype-phenotype relationships.
‘‘The conclusions with respect to the NOD2/CARD15
experience in inflammatory bowel disease have led to
recommendations with respect to clinical classification of
disease’’
In the majority of phenotypic analyses, NOD2/CARD15
mutations are associated with ileal rather than colonic
Crohn’s disease. Meta-analysis demonstrated that the odds
ratio for ileal disease, compared with colonic disease, was 2.5
(confidence intervals 2.0–3.2).14 Association between NOD2/
CARD15 status and complicated Crohn’s disease, fistulising
or stenosing, has emerged. Data from individual studies are
not entirely consistent, reflecting not only the complexity of
disease but also the inconsistency of clinical classifications
used in studies reported thus far. A series of other genotype-
phenotype relationships with respect to the NOD2/CARD15
gene have been examined. Areas that have been subjected to
study, with positive associations, have concluded increased
risk for surgery, lower weight at diagnosis, younger age at
diagnosis, presence of granulomas, and disease response to
drug therapy. Once again, as for serological markers, the
conclusions with respect to the NOD2/CARD15 experience in
inflammatory bowel disease have led to recommendations
with respect to clinical classification of disease.
The investigators examined at some length the contribu-
tion of other genetic determinants of inflammatory bowel
disease. The contribution of the HLA region has been widely
studied, even before genome wide scanning approaches had
implicated the region. Although clear and consistent allelic
associations have now emerged both in Crohn’s disease and
in ulcerative colitis, in addition to associations with extra
intestinal manifestations, the low sensitivity and specificity
of the disease associated allelic variants was again felt to limit
the use in diagnosis and classification. Consistent recom-
mendations emerge from the HLA studies with respect to the
need for rigorous phenotypic classification schemes to be
uniformly adopted; the need for detailed studies of sufficient
magnitude to detect the effects of genetic determinants on
disease susceptibility and on behaviour.1
Other genes and loci discussed included the IBD5 region, a
strongly replicated association, but a region for which the causal
genes are as yet unproven, and the roles of the multidrug
resistance 1 (MDR1), drosophila discs large homologue (DLG5),
and toll-like receptor 4 (TLR4) genes. Current studies implicat-
ing these novel genetic determinants suggest that geographical
together with ethnic variations exist, and moreover genotype-
phenotype relationships of potential value are also present.
However, evidence to implicate any individual marker at the
moment was felt insufficient to recommend applicability in a
classification scheme.1
The changes suggested to the Vienna classification for
Crohn’s disease for age of diagnosis, disease location, and
behaviour may benefit investigating relationships between
genotype and phenotype, notably the distinction between
perianal fistulising and abdominal fistulising disease.
Incorporation of an ulcerative colitis classification system into
the Montreal classification is also of key importance; specifi-
cally, many of the genetic and serological findings apply
uniquely to the group with E3 ulcerative colitis. The issue of
disease progression for both Crohn’s disease and ulcerative
colitis is critical in studies relating genotype to phenotype, as
disease behaviour and severity will undoubtedly change over
time and it will be critical to define the time point at which a
given behaviour might be characterised. The minimal datasets
in genotype-phenotype relationships was thought to be a critical
matter—ethnicity and geographical distribution are both clearly
752 Satsangi, Silverberg, Vermeire, et al
www.gutjnl.com
important. Once again there was uniformity of thought in
recommending the need for parallel prospective studies, using a
commonly accepted minimal dataset for research studies,
which it was thought is likely to be considerably expanded
compared with a purely clinical useful classification scheme.
SUMMARY
The Montreal Working Party has addressed aspects of clinical
definition and classification within inflammatory bowel
disease and the current status of genetic and serological
studies. With respect to Crohn’s disease, ulcerative colitis and
indeterminate colitis, a number of suggestions were made for
refining clinical subclassification, and the use of terminology.
The recommendations with respect to Crohn’s disease and
ulcerative colitis were made so that these might be used in
clinical practice and also for the purposes of future genetic
and serological studies in inflammatory bowel disease. The
course of ulcerative colitis over time is an important aspect of
disease felt to be lacking in robust validated data, such that
recommendations could not be adequately made.
‘‘The recommendations with respect to Crohn’s disease and
ulcerative colitis were made so that these might be used in
clinical practice and also for the purposes of future genetic
and serological studies in inflammatory bowel disease’’
The unsatisfactory use of the term indeterminate colitis was
discussed at length and recommendations for the novel term
IBDU were made. A number of aspects of the Montreal
classification require validation now, and authors have
acknowledged this throughout the document. The need for
independent validation of the classification and assessment of
interobserver variation is likely to be critical, and indeed plans
are underway to compare the relative effect of interobserver
variation in the Montreal classification compared with the
Vienna classification. The goal of integrating molecular and
serological markers is very exciting but is premature at the
present time. Adoption of a uniform minimal data set for
research studies will allow the sensitivity and specificity of
markers available and emerging to be ratified; it is anticipated
that within the next 5–10 years an integrated classification will
become a feasible and sensible reality.
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